330 related articles for article (PubMed ID: 9366300)
1. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA
Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
Bellmunt J; Albanell J; Gallego OS; Ribas A; Vicente P; Carulla J; De Torres J; Morote J; Lopez M; Solé LA
Cancer; 1992 Oct; 70(7):1974-9. PubMed ID: 1525774
[TBL] [Abstract][Full Text] [Related]
5. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
9. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
[TBL] [Abstract][Full Text] [Related]
11. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.
Boutan-Laroze A; Mahjoubi M; Droz JP; Charrot P; Fargeot P; Kerbrat P; Caty A; Voisin PM; Spielmann M; Rey A
Eur J Cancer; 1991; 27(12):1690-4. PubMed ID: 1782084
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
13. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
[TBL] [Abstract][Full Text] [Related]
15. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
Bellmunt J; Ribas A; Albanell J; Bermejo B; Vera R; De Torres JA; Morote J; Lopez-Pacios MA; Banus JM; Rovirosa A; Carulla J; Sole LA
Am J Clin Oncol; 1996 Aug; 19(4):344-8. PubMed ID: 8677901
[TBL] [Abstract][Full Text] [Related]
16. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
Nihon Hinyokika Gakkai Zasshi; 2007 May; 98(4):589-94. PubMed ID: 17564101
[TBL] [Abstract][Full Text] [Related]
17. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Small EJ; Fippin LJ; Ernest ML; Carroll PR
Cancer; 1996 Oct; 78(8):1775-80. PubMed ID: 8859191
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]